Latest Articles
Dr. Sharyn Lewin and patient Kristen Foreman talks about endometrial cancer - WTVM
Dr. Sharyn Lewin and patient Kristen Foreman talks about endometrial cancer WTVM
Published: Oct. 24, 2024, 11:32 p.m.
Chemotherapy Combinations and the Phase 3 DUO-E Trial - Cancer Network
Chemotherapy Combinations and the Phase 3 DUO-E Trial Cancer Network
Published: Oct. 24, 2024, 6:32 p.m.
Neoadjuvant Treatment Considerations for Endometrial Cancer - Cancer Network
Neoadjuvant Treatment Considerations for Endometrial Cancer Cancer Network
Published: Oct. 24, 2024, 6:19 p.m.
Molecular Classification of Endometrial Cancer - Cancer Network
Molecular Classification of Endometrial Cancer Cancer Network
Published: Oct. 24, 2024, 6:19 p.m.
Overview of Endometrial Cancer - Cancer Network
Overview of Endometrial Cancer Cancer Network
Published: Oct. 24, 2024, 6:14 p.m.
Pembrolizumab Earns EU Approval in 2 New Indications for Endometrial and Cervical Cancer - OncLive
Pembrolizumab Earns EU Approval in 2 New Indications for Endometrial and Cervical Cancer OncLive
Published: Oct. 24, 2024, 3:55 p.m.
Pharmacokinetic Relationship Between GLP-1s, Endometrial Cancer Cell Growth - DocWire News
Pharmacokinetic Relationship Between GLP-1s, Endometrial Cancer Cell Growth DocWire News
Published: Oct. 24, 2024, 2:55 p.m.
Episode 6: The Evolving Role of Radiation Therapy in Endometrial Cancer - Medscape
Episode 6: The Evolving Role of Radiation Therapy in Endometrial Cancer Medscape
Published: Oct. 24, 2024, 1:44 p.m.
Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers - BioSpace
Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers BioSpace
Published: Oct. 24, 2024, 11:46 a.m.
Approval From European Commission With Two New Indications in Gynecologic Cancers - businesswire.com
Approval From European Commission With Two New Indications in Gynecologic Cancers businesswire.com
Published: Oct. 24, 2024, 10:45 a.m.
Link copied to clipboard!